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Association between Galectin-3 
levels within central and peripheral 
venous blood, and adverse left 
ventricular remodelling after first 
acute myocardial infarction
olivera M. Andrejic1, Rada M. Vucic  2,3, Milan pavlovic4,5, Lana Mcclements6, 
Dragana Stokanovic7, tatjana Jevtovic–Stoimenov8 & Valentina n. nikolic7
Our study investigates association between Galectin-3 levels and adverse left ventricular remodelling 
(LVR) at six months. Fifty-seven patients following first acute myocardial infarction (AMI) were enrolled 
in this study and blood samples collected on day 1 from the femoral vein and artery, the right atrium 
near the coronary sinus and the aortic root, and on day 30, from the cubital vein. Patients with LVESV 
≥20% at six months, were included in the LVR group. On day 1, Galectin-3 plasma levels in the femoral 
vein (10.34 ng/ml ± 3.81 vs 8.22 ng/ml ± 2.34, p = 0.01), and near coronary sinus (10.7 ng/ml ± 3.97 vs 
8.41 ng/ml ± 2.56, p = 0.007) were higher in the LVR group. Positive correlations between Galectin-3 
levels from aortic root and coronary sinus, aortic root and femoral vein, and coronary sinus and femoral 
vein, were observed in both groups. On day 30, Galectin-3 concentration in the cubital vein was an 
independent risk factor of LVR six months post-AMI, demonstrating 1.5-fold increased risk. Day-30 
Galectin-3 also showed positive correlations with echocardiography parameters indicative of diastolic 
and systolic dysfunction. Determining Galectin-3 plasma concentration on day 30 following AMI could 
have beneficial prognostic value in predicting LVR.
Left ventricular remodelling (LVR) is a set of changes in the ventricular structure and function following acute 
myocardial infarction (AMI), associated with a progressive increase in left ventricular end-systolic volume 
(LVESV) and left ventricular end-diastolic volume (LVEDV). These changes can lead to deterioration of the 
left ventricular systolic function measured by left ventricle ejection fraction (LVEF) and further cardiovascular 
complications1,2. Structural changes of the left ventricle occur in the necrotic area of the infarcted myocardium, 
border zone and remote zone in the non-infarcted myocardium. These changes are characterized by an increase 
in the myocardial infarction area, collagen deposits, scar formation, and hypertrophy of the non-infarcted myo-
cardium. Initial increase in collagen and formation of fibrotic tissue lead to a decrease in ventricular wall tension 
and aid preservation of the shape and contractile function of the left ventricle in the early period following AMI, 
but excessive and prolonged collagen production post-AMI is associated with adverse LVR3.
Following AMI, local and systemic pro-inflammatory factors have an important role in LVR4. Increased col-
lagen production leading to fibrosis, is a result of cardiac fibroblasts activation in response to mediators such as 
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transforming growth factor β (TGF-β) or activation of the renin-angiotensin-aldosterone system4. Galectin-3 is 
another mediator which has a role in the LVR process. High levels of Galectin-3 have been detected in activated 
macrophages following myocardial injury, and its role in stimulating cardiac fibroblasts to synthesize collagen 
type I is well-established5. High systemic and cardiac levels of Galectin-3 have been positively correlated with 
the number of infiltrating macrophages and deposition of extracellular matrix5,6. The pro-inflammatory and 
pro-fibrotic protective roles of Galectin-3, in the early phase of AMI, play an important role in myocardium tissue 
repair7. However, continuous and excessive activation of inflammation and fibrosis, along with high levels of 
Galectin-3, are associated with LVR and poor clinical outcomes8–11. Therefore, determining the localization and 
timing of the positive and negative prognostic value of Galectin-3 in terms of LVR post-AMI is key.
Previous studies have investigated the LVR prognostic value of circulating Galectin-3 levels following AMI 
using blood samples collected from a peripheral vein with conflicting results12,13. Therefore, the aim of our study 
was to investigate association between circulating Galectin-3 levels within central and peripheral arterial and 
venous blood on day 1 and peripheral venous blood on day 30, post-AMI, in short to medium-term LVR. We also 
present detailed analysis of correlations between Galectin-3 levels from each sampling locations as well as corre-
lations between Galectin-3 levels and left ventricular parameters at day 1, 30 and six months after AMI.
Results
clinical characteristics of patients with and without LVR. Six months after AMI, 22 patients with an 
average age of 62.55 ± 9.10 years experienced LVR, whereas 35 patients did not (age: 63.37 ± 10.03). There were 
no differences in demographic characteristics or the vast majority of the co-morbidities between the groups, 
except for the initial higher frequency of diabetes mellitus in the group of patients who developed LVR six months 
after AMI (7 vs 13 patients, p < 0.001; Table 1). Patients who experienced LVR had a higher leukocyte count (9.5 
vs 9.0 (×1012/L), p = 0.02) and CRP (13.5 vs 3.4 (mmol/l), p = 0.03) at baseline. There were no significant dif-
ferences in the clinical presentation of AMI and coronary artery infarction lesion localization, between the two 
groups during initial hospitalization (Table 1).
Association between Galectin-3 levels and left ventricular remodelling. Galectin-3 plasma levels 
were higher in patients with LVR in the femoral vein, right atrium near coronary sinus, on the first day of AMI 
(femoral vein: 10.34 ng/ml ± 3.81 vs 8.22 ng/ml ± 2.34, p = 0.01; coronary sinus: 10.71 ng/ml ± 3.97 vs 8.41 ng/
ml ± 2.56, p = 0.007; Table 2), and in the cubital vein at day 30 (10.41 ng/ml ± 4.03 vs 7.28 ng/ml ± 2.85, p = 0.007; 
Table 2). No differences were observed in arterial Galectin-3 levels between patients with and without LVR.
Using multivariate logistic regression modelling, we identified two variables as potential determinants of LVR 
six months after AMI. At day 30 after AMI, an increase in Galectin-3 plasma concentration in the median cubital 
vein of 1 unit, was independently associated with the 1.55-fold (p = 0.01) increased risk of LVR, six months after 
AMI (Table 3), adjusted for age, leukocyte count, CRP and diabetes. Diabetes was a very strong predictor of LVR 
in our study (OR = 68.2, p = 0.004; Table 3). Galectin-3 concentrations in the right atrium near the coronary sinus 
on day 1 and in the median cubital vein on day 30 showed the most promising sensitivity and specificity, based 
on the receiver operating characteristics (ROC) curves, for predicting the risk of developing LVR. Galectin-3 
concentration in the right atrium near the coronary sinus on day 1, at the cut-off value of 9.42 ng/ml (AUC = 
0.691, p = 0.02) showed sensitivity of 66.70% and specificity of 76.47% (Supplementary Fig. 1A) whereas the ROC 
curves in relation to other blood sampling locations on day 1 did not provide significance or satisfactory sensi-
tivity or specificity (Supplementary Fig. 1B–D). More clinically relevant, Galectin-3 concentration in the median 
cubital vein on day 30, based on the cut-off value of 8.87 ng/ml, which was associated with sensitivity of 73.33% 
and specificity of 81.82% (AUC = 0.758, p = 0.006: Fig. 1) for predicting the risk of developing LVR.
Correlations between Galectin-3 levels from different sampling locations. In the group of 
patients with adverse LVR, we observed positive correlation between Galectin-3 plasma concentration in the 
aortic root and femoral vein (r = 0.947, p < 0.001), aortic root and coronary sinus (r = 0.945, p < 0.001), and 
coronary sinus and femoral vein (r = 0.933, p < 0.001; Table 4) on day 1. Similar but weaker correlations were 
also found in patients without LVR, between Galectin-3 concentrations in aortic root and femoral vein (r = 0.436, 
p < 0.05), aortic root and coronary sinus (r = 0.465, p < 0.01), and coronary sinus and femoral vein (r = 0.532, 
p < 0.001, Table 5).
Correlations between Galectin-3 levels and cardiac function. In the LVR group, we observed a 
reduction in the LVESV (32.66 ± 12.13 vs 44.69 ± 13.76, p = 0.02) and LVEDV (68.26 ± 20.50 vs 90.66 ± 25.3, 
p = 0.001) on day 1 compared to no remodelling group (Table 6). LVEF showed a decrease at day 180 (46.86 ± 5.80 
vs 52.46 ± 7.34, p = 0.004; Table 6) in the LVR group compared to no remodelling group. One of the key param-
eters of LV diastolic function, E/E’, was significantly higher in the LVR group at six months (8.78 ± 2.97 vs 
7.45 ± 1.71, p = 0.03; Table 6). We carried out comprehensive correlation analyses of all relevant echocardio-
graphic parameters and Galectin-3 plasma levels, from different locations and time-points post-AMI. Galectin-3 
in the median cubital vein on day 30 was correlated with a number of echocardiographic parameters of systolic 
and diastolic dysfunction at six months: positively with LVESV (r = 0.343, p = 0.03), diameter of LA (r = 0.446, 
p = 0.004), an increase in LVEDV (ΔLVEDV) (r = 0.571, p < 0.001), and an increase in LVESV (ΔLVESV) (0.579, 
p < 0.001), and negatively with LVEF (r = −0.509, p < 0.001) and a decrease in LVEF (ΔLVEF) (r = −0.599, 
p < 0.001; Table 7). A decrease in LVEF (ΔLVEF) was also negatively correlated with Galectin-3 plasma levels 
in the coronary sinus (r = −0.298, p = 0.02), femoral artery (r = −0.481, p = 0.001), femoral vein (r = −0.290, 
p = 0.03) on day 1, and LVEF at six months was negatively correlated with Galectin-3 plasma levels in the femo-
ral artery on day 1 (r = −0.292, p = 0.049; Table 7). An increase in LVESV from day 1 to six months (ΔLVESV) 
was positively correlated with Galectin-3 levels in the femoral vein on day 1 (r = 0.29, p = 0.03; Table 7), and an 
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Variables No LVR (n = 35) LVR (n = 22) t* or Z** or χ2*** p value
Gender (male) 27 (79.40%) 16 (72.70%) 0.355*** 0.563
Age (years) 63.37 ± 10.03 62.55 ± 9.10 0.313* 0.755
Time of pain onset (hours) 10.00 (3.00–20.00) 14.00 (7.00–20.5) 1.709** 0.089
Diabetes mellitus 7 (20%) 13 (59%) 9.063*** 0.000
Atrial fibrillation 3 (8.6%) 2 (9.1%) 0.000*** 1.000
Arterial hypertension 21 (60.0%) 15 (68.2%) 0.389*** 0.553
Hyperlipoproteinemia 13 (37.1%) 6 (27.3%) 0.592*** 0.442
Smoking habit 13 (62.80%) 8 (63.6%) 0.004*** 0.953
BMI(kg/m2) 27.75 ± 3.7 28.57 ± 3.01 0.888* 0.378
Diastolic Blood Pressure (mmHg) 78.40 ± 14.60 72.95 ± 19.25 1.211* 0.231
Systolic Blood Pressure (mmHg) 133.28 ± 23.51 125.59 ± 33.54 1.018* 0.313
Heart Rate (bpm) 75.09 ± 13.81 74.23 ± 15.45 0.218* 0.828
STEMI 22 (62.9%) 13 (59.1%) 0.081*** 0.780
AV block 1 (2.9%) 2 (9.1%) 0.174*** 0.553
VF/VT 5 (14.3%) 4 (9.1%) 0.028*** 0.695
Artery with culprit lesion 12 (37.1%) 10 (45.5%) 3.570*** 0.312
LAD stenosis (%) 60.00 (50.00–100.00) 42.50 (0.00–99.25) 0.008** 0.993
LCx stenosis (%) 70.00 (50.00–99.00) 70.00 (0.00–75.00) 1.008** 0.313
RCA stenosis (%) 60.00 (40.00–80.00) 99.50 (75.00–100.00) 1.290** 0.197
One-vessel disease 6 (17.10%) 6 (27.30%) 0.336*** 0.506
Two-vessel disease 16 (45.70%) 5 (22.70%) 3.086*** 0.080
Multi-vessel disease 15 (42.90%) 11 (50.00%) 0.278*** 0.598
Total Cholesterol (mmol/L) 5.76 ± 1.13 5.84 ± 1.03 0.268* 0.790
Triglycerides (mmol/L) 1.15 (0.91–1.71) 1.76 (1.37–2.04) 0.520** 0.603
LDL (mmol/L) 3.71 ± 1.05 3.73 ± 1.004 0.076* 0.940
HDL (mmol/L) 1.12 ± 0.24 1.06 ± 0.278 0.804* 0.425
Leukocyte count (x1012/L) 9.0 (8.30–11.70) 9.5 (9.17–12.60) 2.404** 0.016
Haemoglobin (g/L) 142.00 (132–142) 130.50 (112.50–154.50) 0.847** 0.397
hsCRP (mg/L) 3.4 (1.35–7.30) 13.50 (4.70–87.20) 2.112** 0.035
proBNP (pg/ml) 250.00 (179–2,071) 1,577 (309.50–4,926) 1.330** 0.182
Creatinine (μmol/L) 87.5 (78.0–99.8) 86.0 (77.5–109.5) 0.025* 0.980
Creatine clearance (ml/min) 82 ± 27.28 88 ± 38.20 0.586* 0.560
Glucose (mmol/l) 6.00 (5.10–8.10) 5.50 (4.63–9.60) 0.635** 0.525
TnT 1.2 (0.7–10.26) 0.51 (0.13–3.08) 0.825** 0.409
CKMB 27 (20–69.5) 20.5 (13–30) 1.109** 0.268
Nitrates 12 (34.3%) 9 (40.9%) 0.255*** 0.614
Furosemide 11 (31.4%) 5 (22.7%) 0.507*** 0.447
Spironolactone 7 (20.0%) 4 (18.2%) 0.000*** 1.000
ACE inhibitors 26 (74.3%) 18 (81.8%) 0.435*** 0.509
Beta blocker 26 (74.3%) 19 (86.4%) 0.570*** 0.335
Calcium channel blockers 3 (8.6%) 4 (18.2%) 0.438*** 0.411
Proton pump inhibitors 15 (42.9%) 13 (59.1%) 1.424*** 0.233
H2 blockers 8 (22.9%) 2 (9.1%) 0.946*** 0.278
Amiodarone 8 (22.9%) 5 (22.7%) 0.000*** 0.991
Dual antiplatelet therapy 32 (91.4%) 21 (95.5) 0.002*** 1.000
Ticagrelor 20 (57.1%) 13 (59.1%) 0.021*** 0.885
Trimetazidine 12 (34.3%) 12 (54.5%) 2.270*** 0.132
Statins 33 (94.3%) 21 (95.5%) 0.000*** 1.000
Table 1. Baseline characteristics of patients with and without adverse left ventricle remodeling. All values are 
presented as mean ± SD or median with interquartile range (IQR) or numbers (%). Two-tailed unpaired t-test 
(normalized distribution; t(p)) or Man-Whitney (non-normalized distribution; Z (p)), and χ2 (p). LVR – left 
ventricular remodelling, STEMI - ST elevation myocardial infarction, AV - atrioventricular, VT/VF- ventricular 
tachycardia/ventricular fibrillation, BMI- body mass index, LMCA – left main coronary artery disease, LAD 
- left anterior descendent artery, LCx - left circumflex artery, RCA - right coronary artery, CRP - C reactive 
protein, proBNP - pro brain natriuretic peptide, TnT-Troponin T, CKMB-creatine kinase isoenzime MB, ACE 
inhibitor -angiotensine converting enzyme inhibitor.
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increase in the LA diameter (ΔLA) between day 1 and six months, was also positively correlated with Galectin-3 
levels in the femoral artery on day 1 (r = 0.331, p = 0.02; Table 7).
Discussion
This is the first study which investigates the predictive biomarker value and dynamics of plasma Galectin-3 in the 
development of adverse LVR, six months post first AMI, using arterial and venous, central and peripheral blood 
collected on day 1 and 30 post-AMI. Here, we also provide extensive analyses of correlations between Galectin-3 
levels at different time points and from different sampling locations after AMI, as well as parameters of cardiac 
function. Galectin-3 levels in the central and peripheral vein on day 1, and in the peripheral vein on day 30, 
following AMI, were positively associated with adverse LVR; whereas arterial Galectin-3 levels did not show any 
association with LVR. Positive correlation was also found between Galectin-3 levels in central and peripheral 
venous blood, as well as central arterial and central or peripheral venous blood, potentially suggesting myocardial 
synthesis of this marker. Galectin-3 plasma levels in the median cubital vein on day 30, demonstrated promising 
predictive value for the development of negative LVR, six months later, which was identified as an independent 
predictor of 1.55-fold increased risk of LVR when adjusted for age, diabetes and inflammatory markers.
Variables No LVR (n = 35) LVR (n = 22) t value p-value
Aortic Root day 1 9.55 ± 5.65 10.22 ± 3.67 0.425 0.693
Femoral Artery day 1 9.29 ± 3.36 10.83 ± 4.29 1.32 0.194
Femoral Vein day 1 8.22 ± 2.34 10.34 ± 3.81 2.589 0.012
Right Atrium near the 
Coronary Sinus day 1 8.41 ± 2.56 10.71 ± 3.97 2.803 0.007
Cubital Vein day 30 7.28 ± 2.85 10.41 ± 4.03 2.775 0.007
Table 2. Galectin 3 plasma concentration (ng/ml) in patients with and without adverse left ventricular 
remodeling. All values are presented as mean ± SD. Two-tailed unpaired t-test (normalized distribution; t(p)). 
LVR – left ventricular remodeling.
Variable Adjusted odds ratio (95% CI) p-value
Diabetes mellitus 68.192 (3.872–1200.838) 0.004
Galectin-3 on day 30 1.554 (1.106–2.183) 0.011
Table 3. Multivariate logistic regression analysis of variable of adverse left ventricular remodelling six months 
after acute myocardial infarction (adjusted for age, leukocyte count and CRP).
Figure 1. ROC curves for predicting the risk of developing adverse left ventricular remodelling based on 
Galectin-3 concentrations in the median cubital vein on day 30.
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LVR occurs in 10–35% of the patients after AMI14, often after an extensive STEMI infarction of the anterior 
wall, even after myocardial reperfusion is achieved by primary percutaneous coronary intervention (PCI)15. In 
our study LVR occurred in approximately 40% of the patients, which is higher than what is reported in other 
studies16,17 potentially due to higher percentage of patients with diabetes mellitus (35%). Other studies have inves-
tigated the role of Galectin-3 levels both in AMI and chronic heart failure, using experimental models of AMI 
and human studies11,13,18,19. We have also shown previously that Galectin-3 levels are elevated after NSTEMI 
AMI in patients with atrial fibrillation20, however, the predictive and mechanistic role of Galectin-3 in LVR post 
AMI is still in its infancy. In our study, patients who developed LVR, had higher levels of inflammatory markers 
(CRP and leukocytes count) at baseline, indicating the role of inflammation in LVR, likely followed by fibrosis; 
all of which are critical processes driving LVR21,22. Galectin-3′s role in inflammation and fibrosis has been well 
established7,10. Our results demonstrated general trend towards an increase in Galectin-3 secretion levels in the 
LVR group with the most predictive values being obtained at day 30 post AMI. Previous reports based on an 
animal MI model which reported that initial Galectin-3 secretion post-MI was mediated by interstitial cardiac 
macrophages6, prompted us to investigate Galectin-3 dynamics from different blood locations and in a timely 
manner. Published data from another animal model where Galectin-3 was knocked out demonstrated that post 
MI, low baseline levels of Galectin-3 were associated with bigger MI area, adverse remodelling and ventricular 
dysfunction, which are likely associated with reduced collagen deposition and macrophage infiltration22. This 
suggests that initial high levels of Galectin-3 post-AMI are protective, whereas prolongation of high levels of 
Galectin-3 are associated with cardiac fibrosis, which is associated with adverse LVR and clinical outcomes12,23,24. 
Therefore, measuring Galectin-3 levels in the AMI phase during early stages might not have a reliable prognostic 
value in terms of adverse LVR.
According to previously published studies, in patients with chronic heart failure, cardiac Galectin-3 expres-
sion is not differentially expressed compared to healthy controls, however it is increased in ischaemic myocar-
dium25. This suggests that the role of Galectin-3 in LVR is more pronounced in previously healthy myocardium 
which becomes ischaemic following AMI. Frunza and colleagues demonstrated that Galectin-3 expression in 
healthy murine hearts is localized within macrophages and atrial cardiomyocytes; 7 days following exposure to 
increased intracranial pressure, Galectin-3 expression is noted in myofibroblasts also, and 28 days lates in ven-
tricular cardiomyocytes26. In support of these findings, another study reported that the expression of Galectin-3 
in cardiomyocytes was correlated with adverse LVR27.
In human studies investigating association between Galectin-3 levels and LVR post-AMI, conflicting results 
were reported. Weir and colleagues showed no clear association between Galectin-3 levels at baseline post-AMI 
and LVR, except in patients with preserved LVEF12 whereas Di Tano and colleagues reported adjusted odds ratio of 
1.2 when Galectin-3 venous plasma levels were measured during the AMI phase, but with a lower predictive value 
when Galectin-3 was evaluated 30 days later13. In the latter study, diabetes was not identified as a risk factor in a 
univariate or multivariate analyses and the groups with and without LVR differed in terms of age and gender. In 
our study 59% of the patients in the LVR group had diabetes mellitus compared to 11.5% in Di Tano et al. study13. 
Variables
Coronary sinus
Day 1
Femoral artery
Day 1
Femoral vein
Day 1
Median cubital vein
Day 30
Aortic root
Day 1
r 0.945 0.084 0.947 0.042
p 0.000 0.757 0.000 0.882
Coronary sinus
Day 1
r 0.084 0.933 0.139
p 0.768 0.000 0.636
Femoral artery
Day 1
r 0.272 −0.176
p 0.308 0.585
Femoral vein
Day 1
r 0.059
p 0.835
Table 4. Correlation between plasma Galectin-3 levels from different locations and time of sample tooking in 
patients with adverse LVR.
Variables
Coronary sinus
Day 1
Femoral artery
Day 1
Femoral vein
Day 1
Median cubital vein
Day 30
Aortic root
Day 1
r 0.465 0.007 0.436 −0.035
p 0.006 0.97 0.011 0.873
Coronary sinus
Day 1
r −0.066 0.532 0.061
p 0.737 0.001 0.782
Femoral artery
Day 1
r 0.112 0.179
p 0.579 0.463
Femoral vein
Day 1
r 0.233
p 0.297
Table 5. Correlation between plasma Galectin-3 levels from different locations and time of sample tooking in 
patients without LVR.
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Also, our study included both NSTEM and STEMI patients whereas Di Tano et al. study included only STEMI 
patients13. Therefore, our cohort of patients was different in terms of the baseline risk factors. Nevertheless, our 
results are somewhat aligned showing, in a multivariate analysis, a 1.5-fold increase in the risk of LVR at six 
months based on Galectin-3 venous levels not during hospitalisation but 30 days after AMI, which is likely more 
reflective of the damaging effects of Galectin-3 rather than initial protective pro-inflammatory effects.
Furthermore, following out detailed analyses of correlations between Galectin-3 levels and cardiac function 
parameters over time, we demonstrated strong correlations between Galectin-3 plasma levels and several echocardi-
ographic parameters which are used to assess LVR. No difference in average heart rate and frequency of arrhythmias 
between the two groups was observed during baseline echocardiography, indicating no influence of other factors 
on these parameters. Parameters of systolic dysfunction and adverse LVR at six months were associated with higher 
Galectin-3 concentration in the venous blood on day 1 whereas parameters of systolic and diastolic dysfunction 
No LVR (n = 35) LVR (n = 22) t* or Z** p-value
Heart Rate (bpm) 75.09 ± 13.81 74.23 ± 15.45 0.218* 0.828
LVEDV 1 day 90.66 ± 25.3 68.26 ± 20.50 3.490* 0.001
LVEDV 30 day 90.45 ± 25.00 81.05 ± 33.63 1.154* 0.254
LVEDV 180 day 85.51 ± 27.50 89.55 ± 33.15 0.498* 0.620
LVESV1 day 44.69 ± 13.76 32.66 ± 12.12 3.333* 0.002
LVESV 30 day 39 (35.00–52.00) 36.50 (21.00–42.75) 1.554** 0.120
LVESV 180 day 42.00 ± 14.46 48.59 ± 18,07 1.519* 0.134
LVEF 1 day 51.49 ± 5.16 53.77 ± 6.35 1.489* 0.142
LVEF 30 day 52.41 ± 7.13 53.05 ± 7.07 0.318* 0.752
LVEF 180 day 52.46 ± 7.34 46.86 ± 5.80 3.027* 0.004
E/А 1 day 0.78 (0.64–1.13) 0.70 (0.56–0.74) 1.165** 0.244
E/А 30 day 0.87 (0.70–1.20) 0.78 (0.62–0.82) 0.028** 0.977
E/А 180 day 0.78 (0.70–1.20) 0.78 (0.62–0.87) 0.164** 0.869
E/Е′ 1 day 8.25 ± 2.97 8.13 ± 2.60 0.158* 0.875
E/Е′ 30 day 7.63 ± 1.78 8.78 ± 2.76 1.836* 0.072
E/Е′ 180 day 7.45 ± 1.71 8.78 ± 2.97 2.160* 0.035
LA 1 day 38.03 ± 5.56 37.91 ± 4.34 0.086* 0.932
LA 30 day 38.63 ± 4.95 37.85 ± 4.95 0.549* 0.585
LA 180 day 38.31 ± 4.89 40.00 ± 4.48 1.290* 0.203
Table 6. Echocardiography parameters used to diagnose systolic and diastolic left ventricular dysfunction on 
day 1, 30 and 180, in patients with and without left ventricular remodelling, six months after acute myocardial 
infarction. All values are presented as mean ± SD or median with interquartile range (IQR). Two-tailed 
unpaired t-test (normalized distribution; t(p)) or Man-Whitney (non-normalized distribution; Z (p)).  
LVR – left ventricular remodeling.
Variables
Aortic root 
Day 1
Coronary sinus 
Day 1
Femoral artery 
Day 1
Femoral vein 
Day 1
Median cubital 
vein Day 30
LVEDV
180 day
r 0.023 0.120 0.034 0.159 0.276
p 0.860 0.383 0.823 0.232 0.090
LVESV
180 day
r 0.039 0.086 0.098 0.156 0.343
p 0.769 0.522 0.516 0.241 0.033
LVEF
180 day
r −0.164 −0.160 −0.292 −0.227 −0.509
p 0.215 0.224 0.049 0.086 <0.001
LA
180 day
r 0.021 0.234 0.163 0.173 0.446
p 0.876 0.094 0.280 0.194 0.004
ΔLVEDV
r 0.166 0.219 0.124 0.252 0.571
p 0.209 0.102 0.412 0.057 <0.001
ΔLVESV
r 0.166 0.237 0.226 0.290 0.579
p 0.210 0.076 0.131 0.027 <0.001
ΔLVEF
r −0.149 −0.298 −0.481 −0.290 −0.599
p 0.261 0.024 0.001 0.027 <0.001
ΔLA
r 0.244 0.068 0.331 0.108 0.274
p 0.063 0.614 0.025 0.422 0.091
Table 7. Correlation between plasma Galectin-3 levels and echocardiography parameters determined 6 months 
after acute myocardial infarction. Δ – Change from Day 1 to day 180 or six months.
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were associated with higher Galectin-3 levels in the arterial blood on day 1. On day 30 higher Galectin-3 levels were 
associated with parameters of LVR, diastolic and systolic cardiac dysfunction at six months after AMI.
LVR is characterized by deterioration of LV function in systole, as well as in diastole. After AMI, a disor-
der of LV function in early diastole may develop in the form of impaired relaxation, and in the late diastole, 
filling pressure of the ventricle may be increased, due to the reduction in ventricular compliance. The reduced 
diastolic function represents one of the consequences of LVR syndrome after AMI28. According to our results, 
impaired LV function in diastole and increased filling pressure of LV in diastole is accompanied by increased 
Galectin-3 plasma concentration. Similarly, patients with LVR had lower LVESV and LVEDV on day 1. This 
group of patients, six months later had lower LVEF, possibly due to progression of the fibrosis and expansion of 
the infracted myocardial segment as reported before29–31. Di Tano and colleagues demonstrated similar results 
showing that LVEDV on admission was negatively associated with the risk of LVR 6 months post-AMI13.
Limitations of the Study. Our study is unique as it measures Galectin-3 plasma levels in four different 
blood sampling locations including peripheral and central arterial or venous blood, and repeated sampling over 
time for venous peripheral blood. The main limitations of our study are the number of enrolled patients and 
limited 6-month follow-up period. While biomarkers of myocardial necrosis, troponin, and CKMB, were used to 
confirm the diagnosis of AMI, serial measurements of these biomarkers over time, to assess the extent of myocar-
dial necrosis and correlation with Galectin-3 levels, were not performed. Also, as it was not ethically feasible to 
collect heart tissue samples in our study, we were unable to assess cardiac fibrosis or remodelling in these patients 
or to determine exactly the source of Galectin-3 secretion in relation to specific cardiac cell types.
In summary, we have demonstrated that Galectin-3 plasma levels in both central and peripheral venous blood 
on day 1 were increased in patients who developed LVR six months after AMI. No significant changes were 
observed in arterial blood. The most promising prognostic value was demonstrated with high levels of Galectin-3 
in the cubital vein on day 30, which were independently associated with the 1.5-fold increased risk of LVR, six 
months after AMI. We have also demonstrated positive correlations between Galectin-3 concentration from dif-
ferent locations within arterial and venous blood and echocardiography parameters associated with diastolic and 
systolic dysfunction. Determining Galectin-3 plasma concentration at an appropriate time in patients post AMI, 
has both prognostic and therapeutic potential in identifying patients at risk of developing LVR.
Methods
Study participants. Fifty-seven patients experiencing a first AMI were enrolled in this study from 
December 2016 until November 2018. Non-invasive and invasive diagnostic procedures, pharmacotherapy, as 
well as myocardial revascularization by PCI, were performed in accordance with the institutional guidelines and 
the International Cardiology Associations recommendations. The patients who initially had severely impaired 
renal function (GFR < 30 ml/min), systemic inflammatory diseases, cancer, or other valid reasons preventing 
their participation in this study, were excluded. The written informed consent was obtained from all participants 
prior to their inclusion in the study. The research was performed in accordance with the Helsinki Declaration and 
approved by the Ethics Committees of the Faculty of Medicine in Nis and Clinical Centre “Kragujevac”.
Variables of interest. In all patients with AMI, blood sampling was carried out within the first 24 h, during 
PCI. Galectin-3 concentration was measured on day one in central and peripheral arterial blood i.e. in the aor-
tic root and the femoral artery, and in the central and peripheral venous blood i.e. in the right atrium near the 
coronary sinus and the femoral vein, and on day 30, in the cubital vein, following AMI (Supplementary Fig. 2). 
Plasma was separated from the whole blood by centrifugation at 3,000 g for 10 min at 25 °C, aliquoted and frozen 
at −80 °C. Commercially available ELISA kit (BGM, Inc., Waltham, MA, USA) was used to determine Galectin-3 
plasma levels according to the manufacturer’s instruction.
Echocardiography was performed on day 1, 30 and 180 or six months following AMI and the following param-
eters were evaluated: LVEDV, LVESV, LVEF (biplane area-length echocardiography method using Simpson’s for-
mula26), ratio of mitral flow velocity in early and late diastole (E/A), the ratio of mitral flow velocity and mitral 
annulus velocity in early diastole (E/E’), and left atrium (LA) diameter. There are no clear recommendations for 
the diagnosis of LVR, previously reported studies had a variety of definitions, and in our study LVR was defined 
as an increase in LVESV ≥ 20% six months following AMI which separated patients with definitive diagnosis of 
LVR. Physicians who performed echocardiographic assessments were blinded to the biomarker results.
Routine blood tests were performed within the first 24 h of AMI. In addition to routine clinical parameters, 
the levels of hsCRP and proBNP were also measured. Biomarkers of myocardial necrosis, troponin and CKMB, 
were quantified to confirm the diagnosis of AMI. Serial testing of these biomarkers over time, to assess the extent 
of myocardial necrosis, was not performed.
Statistical analysis. The obtained data were processed using the Statistical Package for Social Sciences 
(SPSS, v. 21.0; Chicago, IL, USA). Continuous variables were presented as the mean value with standard deviation 
or median with interquartile range, and categorical variables as absolute numbers of cases with the percentage. 
The differences between two groups were tested using Student’s t-test or Mann-Whitney U-test, depending on 
the normality of the continuous data distribution, or using the χ2-independence test with Yates’s correction 
for continuity of categorical variables. The correlation between two continuous variables was assessed based on 
the Pearson’s correlation coefficient. The influence of putative risk factors on dichotomous outcome was exam-
ined by stepwise multivariate logistic regression analysis with backward elimination of each insignificant variable 
(p ≥ 0.1), and the results were expressed as adjusted odds ratios with respective 95% confidence intervals. The 
diagnostic value of Galectin-3 concentrations in different blood sampling locations at different time points were 
investigated by constructions of the ROC curves. The statistical significance was determined as p < 0.05.
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